Bosch Pharmaceuticals (Pvt) Ltd.
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer with multiple production plants and a broad local and export portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Bosch Pharmaceuticals (Pvt) Ltd
- Company type
- Private pharmaceutical manufacturer
- Address
- 8, Modern Society, Tipu Sultan Road, Karachi-75350, Pakistan · 75350
- Website
- bosch-pharma.com ↗
- Phone
- +92 21 111 126 724
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| A-81-E | Acetylsalicylic acid (Aspirin) | 81 mg | Tablet | 3 × 10's | 091002 | PKR 48.04 | PKR 1.60/tablet | 12% below median |
| Amkay | Amikacin | 100 mg/2 mL | Injection | 5’s | 025419 | PKR 339.77 | PKR 67.95/vial/unit | 20% below median |
| Amkay | Amikacin | 100 mg/2 mL | Solution for injection | 1’s | 025419 | PKR 97.07 | PKR 97.07/vial/unit | No comparator |
| Amkay | Amikacin | 250 mg/2 mL | Injection | 5’s | 025420 | PKR 630.99 | PKR 126.20/vial/unit | 9% below median |
| Amkay | Amikacin | 250 mg/2 mL | Solution for injection | 1’s | 025420 | PKR 174.74 | PKR 174.74/vial/unit | 28% above median |
| Amkay | Amikacin | 500 mg/2 mL | Injection | 5’s | 025421 | PKR 1,213.44 | PKR 242.69/vial/unit | 15% below median |
| Amkay | Amikacin | 500 mg/2 mL | Solution for injection | 1’s | 025421 | PKR 291.22 | PKR 291.22/vial/unit | No comparator |
| Amkay | Amikacin | 25 mg/mL | Solution for injection | 1’s | 027163 | PKR 42.71 | PKR 42.71/vial/unit | 10% above median |
| Amkay | Amikacin | 25 mg | Injection | 5’s | 027163 | PKR 203.86 | PKR 40.77/vial/unit | 5% above median |
| Amkay | Amikacin | 25 mg | Injection | 1’s | 027163 | PKR 42.71 | PKR 42.71/vial/unit | 10% above median |
| Amkay | Amikacin | 50 mg/mL | Solution for injection | 1’s | 027164 | PKR 54.37 | PKR 54.37/vial/unit | 12% above median |
| Amkay | Amikacin | 50 mg | Injection | 5’s | 027164 | PKR 252.39 | PKR 50.48/vial/unit | Near median |
| Amkay | Amikacin | 50 mg | Injection | 1’s | 027164 | PKR 54.37 | PKR 54.37/vial/unit | 13% above median |
| Amkay | Amikacin | 1 g/4 mL | Injection | 1's | 050502 | PKR 403.82 | PKR 403.82/vial/unit | Near median |
| Ampin | Ampicillin | 250 mg | Injection | 1's | 015908 | PKR 67.17 | PKR 67.17/vial/unit | Near median |
| Ampin | Ampicillin | 500 mg | Injection | 1's | 015957 | PKR 86.86 | PKR 86.86/vial/unit | 20% above median |
| Ampin | Ampicillin | 1 g | Injection | 1's | 016930 | PKR 128.55 | PKR 128.55/vial/unit | Near median |
| Apibosh | Apixaban | 5 mg | Tablet | 30's | 110406 | PKR 3,294.03 | PKR 109.80/tablet | 12% below median |
| Apibosh | Apixaban | 2.5 mg | Tablet | 30's | 110407 | PKR 3,098.63 | PKR 103.29/tablet | 11% below median |
| Bestrax-50 | Atracurium besylate | 50 mg/5 mL | Injection | 5mL × 1's | 039185 | PKR 262.09 | PKR 52.42/mL | 21% above median |
| Biofos | Fosfomycin | 1 g | Injection | 10's | 025415 | PKR 156.67 | PKR 15.67/vial/unit | 91% below median |
| Bkay | Amikacin | 500 mg/2 mL | Injection | 2ml × 5's | 100302 | PKR 855.85 | PKR 85.59/mL | 20% below median |
| Bkay | Amikacin | 100 mg/2 mL | Injection | 2ml × 5's | 100303 | PKR 303.48 | PKR 30.35/mL | 22% below median |
| Bkay | Amikacin | 50 mg | Injection | 1ml × 5's | 100304 | PKR 184.66 | PKR 36.93/mL | 24% below median |
| Bkay | Amikacin | 250 mg/mL | Injection | 1's | 114484 | PKR 136.32 | PKR 136.32/vial/unit | No comparator |
| Bkay | Amikacin | 250 mg | Injection | 1's | 114484 | PKR 136.32 | PKR 136.32/vial/unit | 43% below median |
| Bofalgan | Paracetamol | 500 mg | Tablet | 200's | 015112 | PKR 705.01 | PKR 3.53/tablet | Near median |
| Bosch-C | Ascorbic acid | 500 mg | Chewable tablet | 4 × 10's | 110183 | PKR 45.55 | PKR 1.14/tablet | 14% below median |
| Boschempa | Empagliflozin | 10 mg | Tablet | 14's | 112458 | PKR 986.89 | PKR 70.49/tablet | 15% below median |
| Boschempa | Empagliflozin | 25 mg | Tablet | 14's | 112459 | PKR 1,181.23 | PKR 84.37/tablet | 16% below median |
| Boschoclox | Cloxacillin | 250 mg | Injection | 1's | 015906 | PKR 52.72 | PKR 52.72/vial/unit | No comparator |
| Boschofen | Ibuprofen | 200 mg | Tablet | 500's | 015114 | PKR 577.60 | PKR 1.16/tablet | 50% below median |
| Boschofen | Ibuprofen | 400 mg | Tablet | 250's | 015115 | PKR 558.07 | PKR 2.23/tablet | 36% below median |
| Boschofen | Ibuprofen | 400 mg/100 mL | IV infusion | 1's | 105334 | PKR 330.14 | PKR 330.14/vial/unit | 23% below median |
| Boschofen | Ibuprofen | 600 mg/100 mL | IV infusion | 1's | 120103 | PKR 271.62 | PKR 271.62/vial/unit | No comparator |
| Boschofen | Ibuprofen | 400 mg/4 mL | Injection | 1's | 120104 | PKR 194.15 | PKR 194.15/vial/unit | No comparator |
| Boschtrim | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 200's | 015928 | PKR 543.27 | PKR 2.72/tablet | 20% above median |
| Boschtrim DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100's | 015929 | PKR 969.34 | PKR 9.69/tablet | Near median |
| Bosovel | Sofosbuvir + Velpatasvir | 400 mg + 100 mg | Tablet | 28's | 094785 | PKR 19,415.00 | PKR 693.39/tablet | Near median |
| Btrol | Tranexamic acid | 250 mg | Injection | 5's | 030790 | PKR 279.59 | PKR 55.92/vial/unit | 10% below median |
| Btrol | Tranexamic acid | 250 mg | Injection | 1's | 030790 | PKR 58.25 | PKR 58.25/vial/unit | 6% below median |
| Btrol | Tranexamic acid | 250 mg | Injection | 10's | 030790 | PKR 582.45 | PKR 58.25/vial/unit | 6% below median |
| Btrol | Tranexamic acid | 500 mg/5 mL | Injection | 1's | 030791 | PKR 113.18 | PKR 113.18/vial/unit | 28% below median |
| Bucan | Bupivacaine | 0.5% | Injection | 5 × 10ml | 039196 | PKR 210.78 | PKR 4.22/mL | 82% below median |
| Bupro-SR | Bupropion | 100 mg | Sustained-release tablet | 60's | 070849 | PKR 1,096.68 | PKR 18.28/tablet | Near median |
| Bupro-SR | Bupropion | 100 mg | Sustained-release tablet | 10's | 070849 | PKR 198.44 | PKR 19.84/tablet | 9% above median |
| Bupro-SR | Bupropion | 100 mg | Sustained-release tablet | 20's | 070849 | PKR 376.01 | PKR 18.80/tablet | Near median |
| Bupro-SR | Bupropion | 100 mg | Sustained-release tablet | 30's | 070849 | PKR 547.30 | PKR 18.24/tablet | Near median |
| Bupro-SR | Bupropion | 200 mg | Sustained-release tablet | 30's | 070850 | PKR 1,153.08 | PKR 38.44/tablet | 6% below median |
| Bupro-SR | Bupropion | 200 mg | Sustained-release tablet | 10's | 070850 | PKR 417.78 | PKR 41.78/tablet | 7% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.